Biotech companies at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

67 biotech companies are at ObesityWeek 2026 — 87 presentations on the program and 10 with a booth in the exhibit hall. Most represented: Wave Life Sciences (4 on the program), Deep Apple Therapeutics (4 on the program), ProLynx (3 on the program). 21 of them have their own page in this guide. As of Nov 12, 2026.

All 616 organizations at ObesityWeek 2026 →

Topic
Top represented
Showing 1–11 of 67 organizations
OrganizationObesityWeek 2026 Attendance
Wave Life Sciences
Cambridge, MA
◇Bronze Sponsor
BiotechBronze Sponsor
RNA medicines company whose pipeline includes WVE-007 for obesity, plus programs in alpha-1 antitrypsin deficiency and PNPLA3-linked liver disease.
Booth
Exhibiting at Booth 428
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Talk
Sat Nov 14
11:45am–1:15pm
Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made of?
Asks whether body composition, not weight loss alone, should measure obesity treatment success, and reviews activin E biology and small interfering RNA drugs.
Riverview Ballroom A
with knownwell
Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development
Talk
Sat Nov 14
11:55am–12:10pm
Changing the Treatment Paradigm in Overweight and Obesity Management
Riverview Ballroom A
with knownwell, Brigham and Women's Hospital
Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development
Talk
Sat Nov 14
12:10pm–12:35pm
Beyond The Scale: The Clinical Relevance of Body Composition, Body Fat Distribution and Lean Mass
Riverview Ballroom A
with knownwell, Brigham and Women's Hospital
Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development
Talk
Sat Nov 14
12:35pm–1:00pm
From Genetic Evidence to Therapeutic Hypothesis: the INHBE-Activin E Pathway as a Target for Obesity Management
Riverview Ballroom A
Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development
Talk
Sat Nov 14
1:10pm–1:15pm
Rethinking Success: Where Should Obesity Treatment Go?
Riverview Ballroom A
with knownwell
Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development
Poster
Sun Nov 15
2:30pm–3:30pm
Biotech
Drug discovery company using cryo-EM and AI to find oral small molecules for obesity targets such as MC4R, GIPR and amylin receptors.
Poster
Sun Nov 15
2:30pm–3:30pm
Poster
Sun Nov 15
2:30pm–3:30pm
P
ProLynx
San Francisco, CA
Biotech
Biotech using a linker platform to make ultralong-acting anti-obesity peptide therapeutics.
Poster
Sat Nov 14
7:30pm–8:30pm
Poster
Sat Nov 14
7:30pm–8:30pm
Poster
Sat Nov 14
7:30pm–8:30pm
RP
Rivus Pharmaceuticals
Charlottesville, VA
Biotech
Develops obesity and metabolic drugs aimed at fat loss while preserving muscle, including a preclinical GLP-1 receptor agonist.
Poster
Sat Nov 14
7:30pm–8:30pm
◇Bronze Sponsor
BiotechBronze Sponsor
Clinical-stage biotech building a portfolio of obesity medicines meant to give patients options at each stage of treatment.
Booth
Exhibiting at Booth Suite 17
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Poster
Mon Nov 16
2:30pm–3:30pm
Biotech
Drug developer working on oral small-molecule GLP-1 and GIP receptor agonists for obesity.
Poster
Sun Nov 15
2:30pm–3:30pm
Discovery of AMB-895, a Long-Acting and Novel, Oral Small Molecule GLP-1 Receptor Agonist
Obesity pharmacotherapy and drug developmentInterventional and clinical studies
Poster
Sun Nov 15
2:30pm–3:30pm
Biotech
Biotech developing NAMPT activators, with obesity and metabolic disease among its programs.
Poster
Sat Nov 14
7:30pm–8:30pm
Weight-of-Evidence Carcinogenicity Risk Assessment of the NAMPT Activator SIR4156 in Obesity
Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology
Biotech
Developer of antibody-peptide conjugates, working on anti-myostatin and anti-GIPR candidates for obesity.
Poster
Sat Nov 14
7:30pm–8:30pm
Poster
Sat Nov 14
7:30pm–8:30pm
SB
Syntis Bio
Boston, MA
Biotech
Develops a once-daily oral pill that temporarily coats the upper small intestine to mimic the metabolic effects of gastric bypass.
Poster
Mon Nov 16
2:30pm–3:30pm
Poster
Mon Nov 16
2:30pm–3:30pm
◇Bronze Sponsor
BiotechBronze Sponsor
Develops investigational therapies for endocrine and neurodegenerative conditions, including treatment for hypoglycemia after bariatric surgery.
Booth
Exhibiting at Booth 701, Suite 1
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Session
Sun Nov 15
5:30pm–8:00pm
◆Silver Sponsor
BiotechSilver Sponsor
Biopharmaceutical company developing precision medicines for rare neuroendocrine diseases, including acquired hypothalamic obesity.
Booth
Exhibiting at Booth 401
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Talk
Sun Nov 15
12:00pm–1:00pm
Defining Acquired Hypothalamic Obesity: An International Expert Consensus on Diagnostic Criteria in Children and Adults
Unveils 2026 international consensus criteria for diagnosing acquired hypothalamic obesity, a rare form caused by hypothalamic damage, in children and adults.
Riverview Ballroom B
with Seattle Children's Research Institute
Policy and public health
Talk
Mon Nov 16
7:30am–8:30am
The Obesity Diagnosis You May Be Missing: Acquired Hypothalamic Obesity
Case-based guide to spotting obesity caused by hypothalamic damage from tumors, brain injury or stroke, with Phase 3 results for a targeted drug.
with Michigan State University
Clinical obesity care and professional practicePediatric and adolescent obesityObesity pharmacotherapy and drug developmentNeuroscience of appetite and eatingInterventional and clinical studies

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from biotech companies

Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse ObesityWeek 2026 by

Exhibit hall

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction